Orchard Therapeutics plc’s $128 Million Follow-On Offering


Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the approximately $128 million follow-on offering by Orchard Therapeutics plc of 9,000,000 American Depositary Shares, each representing one ordinary share.

The ADSs are listed on the Nasdaq Global Select Market under the symbol “ORTX.”

J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Cowen and Company, LLC and Barclays Capital Inc. acted as joint book-running managers on the deal.

Headquartered in London, United Kingdom, Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies. Orchard’s advanced portfolio of autologous ex vivo gene therapies targets serious and life-threatening rare diseases, initially primary immune deficiencies, neurometabolic disorders and hemoglobinopathies.

Goodwin Procter LLP advised Orchard Therapeutics on the deal.

The Davis Polk capital markets team included partner Deanna L. Kirkpatrick (Picture) and associates Rahim Manji and Cameron Adamson. Partner David R. Bauer and associate Tilak Koilvaram provided intellectual property and technology advice. The tax team included partners Po Sit and Jonathan Cooklin and associates Rosie Upstill and Jonathan Saltz. Counsel Marcie A. Goldstein provided FINRA advice.

Involved fees earner: Cameron Adamson – Davis Polk & Wardwell; David Bauer – Davis Polk & Wardwell; Jonathan Cooklin – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Deanna Kirkpatrick – Davis Polk & Wardwell; Tilak Koilvaram – Davis Polk & Wardwell; Rahim Manji – Davis Polk & Wardwell; Jonathan Saltz – Davis Polk & Wardwell; Po Sit – Davis Polk & Wardwell; Rosie Upstill – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Barclays Capital ; Cowen and Company; Goldman Sachs & Co.; J.P. Morgan Securities LLC;